Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D8CFX3
|
|||
| Drug Name |
REGN6569
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Squamous head and neck cell carcinom [ICD-11: 2D60.0; ICD-10: C77.0] | Phase 1 | [1] | |
| Company |
Regeneron Pharmaceuticals
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Activation-inducible TNFR family receptor (TNFRSF18) | Target Info | Inhibitor | [2] |
| KEGG Pathway | Cytokine-cytokine receptor interaction | |||
| NetPath Pathway | TCR Signaling Pathway | |||
| Pathway Interaction Database | Downstream signaling in naï | |||
| Reactome | TNFs bind their physiological receptors | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT04465487) Study of REGN6569 and Cemiplimab in Adult Patients With Advanced Solid Tumor Malignancies. U.S. National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of Regeneron Pharmaceuticals. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.